- Home
- ACRE vs SLN Comparison
ACRE vs SLN Comparison
Compare ACRE & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRE | SLN |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 116 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 236.2M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRE | SLN |
|---|---|---|
| Price | $4.95 | $6.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $5.38 | ★ $42.60 |
| AVG Volume (30 Days) | ★ 393.8K | 184.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.58% | N/A |
| EPS Growth | ★ 26.17 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $54,833,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.28 | N/A |
| P/E Ratio | $3.66 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.05 | $4.19 |
| 52 Week High | $5.89 | $8.40 |
Technical Indicators
Market Signals| Indicator | ACRE | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 49.98 | 52.19 |
| Support Level | $4.65 | $5.76 |
| Resistance Level | $5.15 | $7.53 |
| Average True Range (ATR) | 0.13 | 0.58 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 68.18 | 66.18 |
Price Performance
Historical ComparisonAbout ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.